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Summary 
CR1/CR2 chimeric receptors in which various short consensus repeats (SCRs)  of CR1 were 
attached to CR2 were transiently expressed  on COS cells, and assessed for the binding ofpolymerized 
C3b (pC3b) and anti-CR2 by immunofluorescence. Of COS cells expressing chimeras containing 
SCR 1-4,  1-3,  2-4,  1-2,  and 2-3 of the long homologous repeats (LHRs) -B or -C, 96%, 
66%, 23%, 0%, and 0%, respectively, bound pC3b.  K562 cells were stably transfected with 
wild-type CR1, deletion mutants of CR1, and the CR1/CR2 chimeras, respectively, and assayed 
for binding of 12SI-pC3b. The dissociation constants  (Kd) for pC3b of wild-type CR1 and the 
LHR-BD and -CD constructs were in the range of 1.0-2.7 nM, and of the CR1/CR2 chimeras 
containing SCRs 1-4, 1-3, and 2-4 of LHR-B or -C were 1.8-2.4, 6-9, and 22-36 nM, respectively. 
The factor I-cofactor function of the CR1/CR2 chimeras paralleled the C3b-binding function 
of the constructs.  A CR1/immunoglobulin (Ig) chimeric protein was prepared by fusing SCRs 
1-4 of LHR-B to the heavy chains of a murine F(ab')2 anti-nitrophenacetyl (NP) monoclonal 
antibody.  The (CR1)2-F(ab')a chimera, which retained its specificity for NP, was as effective as 
soluble, full-length CR1 in binding pC3b,  serving as a cofactor for factor I-mediated cleavage 
of C3b, and inhibiting activation of the alternative pathway, indicating that the bivalent expression 
of these SCRs reconstitutes  the alternative pathway inhibitory function of CR1. The feasibility 
of creating CR1/Ig chimeras makes possible a new strategy of targeting complement inhibition 
by the use of Ig fusion partners  having particular  antigenic specificities. 
C 
R1  (CD35)  was  first  purified  to  homogeneity from 
detergent-solubilized erythrocyte (E) membranes not as 
a receptor but as an inhibitor of the alternative complement 
pathway that resembled  factor H  in its capacity to decay- 
dissociate the C3b,Bb convertase and to serve as a cofactor 
for the cleavage  of C3b by factor I (1). This initial study demon- 
strated  that CR1 was even more inhibitory than factor H, 
especially  when C3b was on an alternative pathway-activating 
surface, a circumstance in which factor H was relatively  ineffec- 
tive (2). Subsequent studies showed that CR1 also promoted 
the factor I-mediated cleavage of iC3b to C3c and C3dg (3, 
4), the dissociation of the dassical pathway convertase, C4b, 
2a, and the factor I-mediated cleavage of C4b to C4c and 
C4d (5, 6). Therefore,  CR1 is unique in having the com- 
bined inhibitory functions of the other members of the regu- 
lators of complement activation (RCA) t family, the plasma 
proteins factor H and C4-bp, and the membrane proteins decay- 
accelerating factor (DAF),  and membrane cofactor protein 
(MCP) (7), and in not being restricted by alternative pathway 
activators, as are factor H and DAF (8). The remarkable in- 
hibitory capability of CR1 was demonstrated when a recom- 
binant soluble form of the receptor, sCR1, suppressed com- 
plement activation in serum by the classical and alternative 
1  Abbreviations  used in thispaper:  BMH, bismaleimidohexane; DAF, decay- 
accelerating factor; LHK, long  homologous  repeat; MCP, membrane 
cofactor protein; NP, 4-hydr~y-3 nitrophenacetyl; pC3b, polymerized  C3b; 
RCA, regulators ofcomplement activation; SCR, short consensus repeat; 
sCR1, recombinant soluble CR1. 
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endogenous concentrations  of factor H  and C4-bp,  and in 
vivo in a model of myocardial reperfusion injury (9). 
The molecular basis for and biologic reactions subserved 
by these functions became apparent with the molecular cloning 
of CK1 (10-12), and the analysis  of its function on E and 
B lymphocytes. CK1 consists of 30 short consensus repeats 
(SCKs) of 60-70 amino acids that are characteristic of com- 
plement proteins  that bind C3,  C4,  and C5.  Four groups 
of seven SCKs are highly homologous, and form long ho- 
mologous repeats (LHRs). By analysis of recombinant dele- 
tion mutants, three of these LHRs were shown to have ligand- 
binding function: LHR-A for C4b, and LHRs-B and -C for 
C3b (11). Thus,  the basis for CR1 having the functions of 
factor H and C4-bp is the occurrence of structurally distinct 
sites  for interacting  with C3b and C4b.  Atkinson  and his 
colleagues (13) have shown recently that substitution of cer- 
tain  residues in  SCKs-1  and  -2 with  residues from corre- 
sponding positions in the homologous SCKs-8 and -9 gener- 
ated  C3b-binding  function  in  LHK-A,  confirming  the 
observation that the first two SClks of each LHR determined 
ligand  specificity (11). 
The biologic purpose of the inhibitory function of CR1 
may be to suppress further complement activation after the 
amounts of C3b and C4b that have been covalently attached 
to an activator are sufficient for mediating uptake by cellular 
receptors.  The inhibitory function of CK1 also causes the 
conversion of C3b to iC3b and C3dg, which are ligands for 
the sigual-transducing  receptors CR2 and CK3. This sequence 
of CKl-mediated uptake of complement-activating complexes, 
followed by processing and transferal to other receptors, may 
occur during the clearance of immune complexes by E (14), 
and may be the functional correlate of the molecular com- 
plex between CR1 and CR2 on B lymphocytes (15). Thus, 
it may be biologically appropriate for CK1 to be the most 
effective inhibitor  among  the  KCA  proteins  because  the 
receptor must suppress the complement-activating functions 
of C3b or C4b whenever these proteins are ligated, whereas 
factor H  and C4-bp, for example, must permit activation by 
certain stimuli, such as microbial cell walls and immune com- 
plexes. 
Determination of the minimal structural requirements for 
a functional CK1 binding  site would enable the construc- 
tion of chimeric proteins having unique capabilities for the 
tissue-specific inhibition of complement activation. The present 
study demonstrates  that,  in addition  to the NH2-terminal 
two SCRs of LHKs-B and -C, the third and fourth SCKs 
are necessary to form a C3b-binding site that is functionally 
equivalent  to  that  of the full-length  receptor,  perhaps  ac- 
counting for these SCKs being the most conserved among 
those of the three ligand-binding  LHKs. A  (CR1)2-F(ab')2 
chimeric protein that contains SCRs 1-4 of LHR-B is con- 
structed and shown to be as effective an inhibitor of the acti- 
vation of the alternative pathway as is sCR1, indicating the 
feasibility of this strategy for the targeting of complement 
inhibition. 
Materials  and Methods 
Antibodies and Complement Proteins.  HB-5 anti-CR2 IgG2a (16), 
YZ-1 anti-CR1 IgG1 (17), anti-C3 (Quidel Corporation, San Diego, 
CA), F(ab')z rabbit anti-CR1  (18), control RPC5.4 IgG2a (Amer- 
ican Type Culture Collection,  Rockville, MD), rabbit anti-sheep 
RBC stroma (hemolysin) (Sigma Chemical Co., St. Louis, MO), 
FITC goat anti-mouse IgG, and Texas Red goat anti-mouse IgG 
(Jackson Immuno Research Laboratories, Inc., West Grove, PA) 
were used. C3 was purified from fresh frozen plasma (19) (Amer- 
ican Red Cross, Baltimore, MD) and converted to C3b with 0.8%o 
(wt/wt) TPCK-trypsin  digestion for 90 s at 37~  Polymerized 
C3b (pC3b) was made by crosslinking concentrated C3b with an 
80-fold M excess of glutaraldehyde (Sigma Chemical Co.) for 2 h 
at room temperature.  Polymers were fractionated over gradients 
of 7.5-40% sucrose (wt/vol) in PBS by centrifugation  at 200,000 
g for 12 h at 4~  After analysis on SDS-PAGE, fractions containing 
tetramers or higher order polymers were pooled, dialyzed, and stor~l 
at 0~  The average molecular weight of pC3b was taken to be 
106. C3b dimers were generated by addition of a 1:4 molar ratio 
of bismaleimidohexane (BMH) (Pierce Chemical Co., Rockford, 
IL)/C3 in the initial trypsin reaction, followed by incubation 2-3 
d at 0~  BMH crosslinks C3b by reacting with the free sulfhydryls 
generated upon hydrolysis of the C3 thiolester. The mixture  was 
fractionated on a Mono Q HR/10 column (Pharmacia LKB Bio- 
technology  Inc., Piscataway, NJ), and fractions containing  cova- 
lently associated dimers were pooled and further  purified by gel 
filtration on a Superose 12 column (Pharmacia LKB Biotechnology, 
Inc.). The preparation contained primarily C3b dimers with "~5% 
C3b monomer contamination  as assessed by Coomassie brilliant 
blue staining of proteins after SDS-PAGE. 
Proteins were iodinated by the Iodo-gen (Pierce Chemical Co.) 
method (20). The specific activities ranged from 0.8 to 2  x  10  + 
cpm/#g. Free tzsI was removed by passing proteins over 5-ml Ex- 
cellulose desalting columns (Pierce Chemical Co.). 
Construction and ExFression of  CR1 Chimeras.  For the DNA en- 
coding CtL1/CtL2 chimeras, various SCRs of CR1 were amplified 
by PCR using the BglI linearized full-length CR1 phsmid, piABCD 
(11), as template, and 25 cycles  of 2 min of denaturation, annealing, 
and  extension.  Primers  were  as  follows:  5'  SCR  8  and  15: 
GCACCCGC,  C~TCCTCGGGATTTCTTGTCAAGCCCCAGA- 
TCAT; 5' SCR 9 and 16: GCACCCGGGGTCCTCGGGATTTC- 
TTGTAAAACTCCTCCAGA~  3' SCR 9 and 16: ACACTCGA- 
GAGACACTCGTTGACAAATTGGCGG;  3'  CR  10  and  17: 
ACACTCGAGAGACACAATGCACTGAGGGGCCGG;  and  3' 
SCR 11 and 18: ACACTCGAGAGACACCCTGGAGCAGCTT- 
GGTAG. Xma I sites were included in the 5' primers and XhoI 
sites in 3' primers. After amplification, fragments were digested 
by XmaI  and XhoI, and ligated into  XhoI- and XmaI-digested 
piCR2.H.  This  plasmid  was  generated  by oligonuchotide-di- 
rected mutagenesis  of pi15, which is the eukaryotic expression 
vector containing  the 15-SCR CR2 isoform in CDM8, to incor- 
porate a silent G to C transversion in the third position of a codon 
encoding a proline residue within the CR2 leader peptide to create 
a unique  XmaI site. The unique  XhoI  site in piCR2.H is be- 
tween SCRs-2 and -3. Chimeras were sequenced on both strands 
throughout the CR1 insert by the dideoxynucleotide chain termi- 
nation  method (21) using  the Sequenase kit  (U.S. Biochemical 
Corp.,  Cleveland, OH). 
For construction of (CR.1)z-F(ab')z, 25 cycles  of PCR were used 
to amplify CR1 SCRs 8-11 using BglI-linearized piABCD as tern- 
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CAGCTGGGTCACTGTCAAGCC,  and 3' SCR 11, GACCTG- 
CAGTTGGACC~ACCCTC-GAGCAGCTTGGTAG.  PstI 
sites were present  in both primers.  The plasmid,  pSV-V~-3,~, 
(provided by M. S. Neuberger, MRC Laboratory of Molecular Bi- 
ology, Cambridge, UK) contains the VDJ, C~1, and hinge regions 
of a mouse 3'z~ gene, transhtion termination  and polyadenyhtion 
sequences from the mouse Cs gene (22), and encodes a secreted 
F(ab')2-1ike molecule with specificity for the hapten  4-hydroxy- 
3-nitrophenacetyl  (NP) when expressed in J558L cells (provided 
by S. L. Morrison,  Molecular Biology Institute,  UCLA, Los An- 
geles, CA), a line expressing an endogenous )~ I chain and no heavy 
chain (23). The 2.2-kb EcoRI-BamHI fragment cont~inlng the VDJ 
region  was removed and cloned into Bluescript  (pBS) to yield 
pBSS'V.. This plasmid was digested with PstI at a unique site im- 
mediately upstream of the VDJ region into which the 800-bp PstI- 
digested CR1 SCRs 8-11 was cloned to generate pBS5'V,-CR1. 
The plasmid, pBSVa.R1, which had been created by cloning the 
4-kb EcoRI fragment from pSV-V~-3'# into pBS, was completely 
digested with XhoI and partially digested with BamHI to remove 
a 2.2-kb fragment, which was replaced by the 3-kb EcoRI-BamHI 
fragment of pBS5'V.-CR1 containing CR.1 SCRs 8-11 upstream 
of the VDJ region,  to create pBSV,-CR1.  The pBSVwCR1 was 
partially digested with EcoRI and the 4.8-kb fragment was cloned 
into EcoRI-digested  pSV-VNp 'y~, to yield pSV-VNp-78-CR1, the 
13-kb expression vector used for transfections. 
The pl~m~ p~a3CD, p~D, piCPa (S-9)/CR~, p~r 
CR2,  piCRI(8-10)/CR2,  piCRl(16-18)/CR2,  and  piCR1(8- 
11)/CR2 were transiently expressed in COS cells using the DEAE- 
dextran procedure (24). K562 cells were cotransfacted by lipofection 
with piABCD, deletion mutants, and the piCR1/CR2 constructs, 
respectively, and p141, a plasmid conferring resistance to hygromycin. 
The cells were selected in hygromycin and sorted for highly ex- 
pressing transfectants as described (25). J558L cells were cotrans- 
fected with pSVneo and pSV-V~o-3,#-CR1  by electroporation using 
960/~P and 350 V, and selected in I mg/ml G418. Cells were dis- 
tributed in cloning  chambers and those secreting high amounts 
of (CR1)2-P(ab')a were identified by ELISA in which molecules 
binding NP were detected with anti-)~ mAb conjugated to horse- 
radish peroxidase  (Fisher Scientific  Co., Pittsburgh, PA). These trans- 
fectants were batch cultured, and (CR1)2-F(ab')2 was purified from 
culture supematants by affanity chromatography  on NP-sepharose 
(26, 27). 
COS cells were maintained in DME (Gibco Laboratories, Grand 
Island, NY) with D-glucose at 4,500 mg/ml supplemented with 
10% bovine calf serum (BCS) (HyClone Laboratories, Logan, UT) 
and 2 mM ghitamine (Gibco Laboratories). K562 erythroleukemia 
and J558L cells were grown in RPMI 1640 (Gibco Laboratories) 
supplemented with 10% BCS (Hyclone Laboratories) and 2 mM 
ghitamine  and penicillin/streptomycin  (Gibco Laboratories). 
Assays  for CR1 Function.  Transiently transfected COS cells were 
assayed 2-3 d post-transfection for the presence of wild-type CR1 
or deletion mutants of CR1 by incubation with YZ-1 followed by 
a  1:40 dilution  of fluorescent goat anti-mouse IgG.  CR1/CR2 
chimeras, which lacked the YZ-1 epitope but contained the HB-5 
epitope of CR2, were detected by substituting  HB-5 for YZ-1. For 
C3b-binding activity of the transient transfectants, replicate samples 
of cells were sequentially incubated with incremental concentra- 
tions of pC3b, a 1:1,000 dilution  of anti-C3,  and the fluorescent 
mAb. Ceils were held on ice in the dark until microscopic exami- 
nation, and 280-500 cells from each slide were analyzed in a blinded 
manner. 
Stably transfected K562 cells expressing various forms of CR1 
were incubated on ice for I h in PBS containing  1% bovine serum 
albumin (PBSA) (Sigma Chemical Co.) and incremental concen- 
trations  of l~I-pC3b in the presence or absence of rabbit  anti- 
CR.1, followed by centrifugation  through 300 #1 of a 3:1 mixture 
of dibutyl/dinonyl  phthalate for 45 s at 7I( at room temperature. 
Tubes were cut above the cell pellets, and bound and free ligand 
were determined. Specific  binding was defined as the amount bound 
of lzSI-pC3b in the absence of anti-CR1  minus that bound in the 
presence of anti-CR1, and was subjected to Scatchard analysis. The 
Ka  values were  determined  by first  order  linear  regression  of 
Scatchard analyses. 
Inhibition of 12sI-pC3b binding to E by (CR1)z-F(ab')z or sCR1 
was assayed in PBSA as above, except that cells were centrifuged 
through neat dibutyl phthalate. 
To assay  factor I-cofactor activity, K562 cells were lysed in buffer 
containing  1% NP-40,  10 mM triethanolamine,  150 mM NaC1, 
1 mM EDTA, and the protease inhibitors leupeptin, pepstatin A, 
chymostatin,  antipain,  and diisopropyl fluorophosphate,  and in- 
soluble material was removed by centrifugation  of the lysates. The 
lysates were precleared by sequential incubation with Trisacryl beads 
bearing protein A (Pierce Chemical Co.), and nonspecific RPC5.4 
IgG2a and Trisacryl-pmtein A, and split into replicate samples which 
were subject to immunoprecipitation  by 5 pg/ml RPC5.4 IgG2a 
and I-IB-5, respectively, and Trisacryl-Protein A. The beads were 
washed five times in ice-cold lysis buffer, and cofactor activity was 
assessed by incubation  with factor I and l'~I-labeled C3b dimers 
for 1 h at 37~  Samples were reduced, boiled, and analyzed on 
5-10%  gradient  SDS-PAGE. Gels were dried  and  exposed  to 
X-OMAT-AR film (Eastman Kodak Co., Rochester, NY) with an 
enhancing  screen for 16-48 h at  -80~  The cofactor activities 
of sCR1 and (CR1)2-F(ab')~ were similarly assayed, except that 
they were not immobilized on beads. 
The chssical pathway inhibitory activities of (CR1)2-F(ab')2 and 
sCR1 were compared by incubating sheep E sensitized with rabbit 
IgM with incremental concentrations of the two recombinant pro- 
teins in normal human  serum diluted  1:160 for 30 rain at 37~ 
Unlysed cells were pelleted by centrifugation  and the supematant 
was assessed for hemoglobin spectrophotometrically. The alterna- 
tive pathway inhibitory activities of (CR1)z-F(ab')z and sCR1 were 
compared by incubating normal human serum diluted 1:5 in veronal 
buffered saline containing  2 mM Mg  z+ and 8 mM EGTA with 1 
mg/ml zymosan and incremental concentrations of the two recom- 
binant  proteins for 20 rain at 37~  after which the generation 
of C3adesArg and C5adesArg was measured by radioimmunoassay 
(Amersham Corp.,  Arlington  Heights,  IL). 
Results 
Mapping of the C3b-binding Site of CRI.  The C3b-binding 
capabilities of wild-type CR1, CR1 ddetion mutants (15), 
and CR1/CR2 chimeras  (Fig.  1) were compared to deter- 
mine the requirements for a functional C3b-binding site. The 
CR1/CR2 chimeras were created by substituting eDNA en- 
coding various PCtL-amplitied SCR.s of CR1 for SCRs-1 and 
-2 of CR2 in an expression vector encoding the 15-SCR iso- 
form of CR2. Transiently transfected COS cells were assayed 
for the ability to bind anti-CR1 or anti-CR2 mAb and pC3b 
by indirect immunofluorescence (Table 1). Essentially all COS 
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Figure  1.  Schematic  representations of (A) full-length CK1 and CK1 
amplified SCRs of CK1 to CR2 lacking its ligand-binding SCK-1 and 
I.  I.  I,oI,,I,,  ,,,;  I I1,~  .,o.,,~o.  +,-o.. 
I,  }.  I,o],,],.I,,i,:I,,  ~  .,o.,,~o.  +,.,,o.. 
I! J, j,O{l,  J12j1"~{.'  I"  ~) p|CRt,$CRe..10)/CR2 
I, t, 1,01',l,.I,.  1,! ? ~:~ .,o.+o..,,~o~ 
deletion mutants and (B) the CR1/CR2 chimeras created by ligating PCR- 
-2. 
Table  1.  Indirect  Fluorescence  Anal)sis of the Binding of mAb and 
pC3b to COS Cells Transiently Transfected with CR1 
Constructs 
pC3b (#g/ml) 
Construct  mAb*  40  10 
piABCD+  8.1"  9.2  6.1 
piBDr  4.7  7.5  5.8 
piCR1 (8-9)/CK2S  10.3  0  ND 
piCK1  (16-17)/CR2S  15.6  0  ND 
piCK1  (16-18)/CR2S  16.1  3.7  0 
piCK1  (8-10)/CR2S  5.6  3.7  0.9 
piCR1 (8-11)/CR2S  7.7  7.4  8.1 
* COS cells transfected  with piABCD and piBD were assessed  with YZ-1, 
and cells transfeeted  with CR1/CR2 chimeras were stained with HB-5. 
* The letter designations of these constructs refer to the LHRs that are 
encoded in the CR1 constructs. 
S The numbers refer to the SCKs of CR1 that are encoded by the chi- 
meric CR1 constructs. 
II Percent of transiently transfected cells staining positively. 
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cells expressing wild-type CR1, piBD, and piCK1 (8-11)/CR2 
bound pC3b, whereas cells expressing piCK1 (8-10)/CR2 
and piCR1 (16-18)/CK2, respectively, were less effective in 
binding pC3b, and neither chimera containing only two of 
the four NH2-terminal SCR of LHK-B or -C bound pC3b. 
To assess the affinities of various CR1 constructs for pC3b, 
replicate samples of stably transfected K562 erythroleukemia 
cells were incubated with incremental concentrations of tzsI- 
pC3b in the presence and absence of polyclonal anti-CR1, 
and cell-bound and free ligand were determined (Fig. 2). Wild- 
type K562 cells and K562 cells expressing piCR1 (16-17)/CR2 
bound  no  mI-pC3b  specifically.  Scatchard analyses  of the 
specific  binding  curves  (Table  2) yielded Ka values in  the 
range of 1.0-2.7 nM for wild-type CR1, the deletion mu- 
tants piBD and piCD, and the piCK1 (8-11)/CR2 chimera, 
a Kd of 6-9 nM for piCR1 (8-10)/CK2,  and a Ka of 22-36 
nM for piCK1 (16-18)/CR2. Therefore, the first four SCKs 
in LHR-B, and presumably of LHR-C, are suffldent and neces- 
sary to form a C3b-binding site with an affinity indistinguish- 
able from that  of the intact LHRs in wild-type CR1 and 
the deletion mutants. The first and fourth of these four SCRs 
contribute to but both are not required for C3b binding, as 
piCK1 (8-10)/CK2 binds pC3b with three- to fivefold lower 
affinity, and piCK1 (16-18)/CR2 with a 15- to 20-fold lower 
affinity than  wild-type CR1. 120000 
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Figure 2.  Saturation  binding of tzsI-pC3b to K562 
ceils stably expressing piABCD (A), the piBD (B) and 
piCD (C) deletion  mutants, and the CR1/CR2 chimeras 
piCRl(8-11)/CR2  (D), piCRI(8-10)/CR2 (E), and 
piCK1 (16-18) (F). Specific  binding (closed  circles)  was cal- 
culated by subtracting nonspecific  binding occurring  in 
the presence  of rabbit anti-CR1 (triangles)  from binding 
in the absence of antibody (squares). 
The CR1/CR2 chimeras containing SCRs 8--11, 8-10, and 
16--18 were assessed for their ability to serve as cofactors for 
factor I-mediated deavage of C3b. Cell lysates ofK562 trans- 
fectants were adjusted to  contain  amounts of CR1/CR2 
chimeras that were equivalent with respect to C3b-binding 
function. Thus, fivefold more CR1 (8-10)/CR2 and 20-fold 
more  CR1  (16-18)/CR2  were  present  than  were  CR1 
(8-11)/CR2. The lysates  were immunoadsorbed with immobi- 
lized H.B-5 or control R.PCS.4 IgG2a, washed, and incubated 
with factor I and 12SI-labded C3b dimers for 1 h  at 37~ 
after which the samples were reduced, boiled, and analyzed 
by 5-10% SDS-PAGE autoradiography (Fig. 3). Dimeric C3b 
was used in this assay to permit higher affinity bivalent inter- 
actions with the immobilized CR1/CR2 chimeras. The BMH 
crosslinking reagent used for generating covalent dimers is 
not reducible, and undigested oe' chains appear as 220-kD 
bands. Cleavage by factor I of the c,' chain releases a 43-kD 
protein from monomeric or dimeric ~  chains, making a band 
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of  this  molecular  mass the  most clearly  detectable  signal  of 
cofactor  activity.  No cleavage  of  C3b occurred  in  reactions 
containing  beads  bearing  nonspec~cally  adsorbed  proteins 
(lanes 7-11).  The CRI  (8-11)/CR2 (lane  4) and CRI 
(8--I0)/CR2  (lane  5)  chimeras  had cofactor  activities  that  were 
nearly  equivalent  when adjusted  for  their  relative  binding  func- 
tions,  whereas  that  of  CRI (16--18)/CR2  (lane  6)  was less, 
although detectable.  Therefore,  the SCRs mediating  the 
cofactor  function  of  CR1 cannot  be  distinguished  dearly  from 
those  that  bind  C3b. 
A  (CR1)a-F(al/)~ Chimera with Inhibitory Function in the Al- 
ternative Complement Pathway.  To determine whether the 
C3b-binding site of CK1 could be functionally expressed on 
another protein lacking SCKS,  the cDNA encoding CR1 
SCKs 8-11 was ligated into a vector containing the trun- 
cated heavy chain of a routine F(ab')z mAb specific for NP 
(Fig. 4). The expression vector was cotransfected with pSVneo 
into J558L cells, which express an appropriate ),1 light chain Table  2.  Summary  of the Affinities  of the CR1  Constructs 
for pC3b 
Construct  Kd  r* 
nM 
piABCD  1.0  -  0.97 
piBD  2.7  -  0.94 
2.1  -0.91 
piCD  1.4  -  0.87 
2.6  -0.82 
piCK1  (8-11)/CK2  2.4  -  0.87 
1.8  -  0.97 
piCK1  (8--10)/CK2  6.2  -0.94 
7.3  -  0.88 
8.7  -  0.82 
piCR1  (16-18)/CR2  36  -0.82 
22  -  0.52 
* Correlation coei~cient of the first order linear regression of the Scatch- 
ard analysis. 
for the NP-specificity  of the recombinant F(ab')2, and the 
resulting (CR1)z-F(ab')2 was purified from culture superna- 
tants of transfected cells by adsorption to and elution from 
NP-sepharose, indicating that the hapten-binding site was in- 
tact. The capacities of (CR1)2-F(ab')2 and sCR1 to bind C3b 
were compared by incubating human E with 12q-pC3b in 
the absence or presence of incremental concentrations of the 
two forms of soluble CR1, and assaying cell-bound radiola- 
beled ligand (Fig. 5). The (CR1)z-F(ab')2 was equivalent to 
sCR1 in its capacity to inhibit competitively the binding of 
CR1 SCR 
I  I 
] 819 ~101111  IoG~  ] 
181"11o1"1  ,.o..  I 
Figure 4.  Schematic  representation of (CR1)2-F(ab')2.  SCR 8-11  of 
CR1 were amplified by PCR and ligated to a vector encoding a truncated 
murine 'YZb  gene which, when transfccted into J558L cells expressing en- 
dogenous M  chain, led to the secretion of a (CK1)2-F(ab')2 chimera. The 
recombinant protein was purified from culture supernatant on NP-sepharose. 
12SI-pC3b  to cellular CR1,  with  50%  inhibition  occurring 
at 20-30 nM for each. 
The factor I-cofactor function of (CR1)2-(Fab')2 was com- 
pared with that of sCR1 by incubating incremental concen- 
trations of each with radiolabeled  C3b dimers and factor I 
for 1 h at 37~  followed by SDS-PAGE and autoradiography 
(Fig. 6). The chimera served to promote the cleavage of all 
dimeric C3b at 9.76  x  10-10 M, with complete conversion 
to dimeric C3dg at 2.50  x  10 -7 M. sCR1 promoted those 
reactions at  approximately fourfold lower concentrations. 
The alternative  pathway inhibitory functions of (CR1)z- 
F(ab')2  and  sCR1  were  compared by  incubating  human 
serum containing Mg  2+ and EGTA with zymosan in the ab- 
sence or presence of incremental concentrations of the two 
recombinant proteins for 20 min at 37~  and assaying for 
the  generation  of  the  C3  and  C5  activation  fragments 
C3adesArg and C5adesArg (Hg. 7). The (CR1)2-F(ab')2 was 
as effective as sCR1 in suppressing the alternative  pathway 
C5 convertase, and approximately one-half as effective in in- 
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Figure 3.  Factor I-cofactor activity 
of  immunoprecipitated  CR1/CR2 
chimeras. K562 stable transfectants e~- 
pressing  piCRl(8-11)/CR2,  piCR1 
(s-10)/cR2, piCRI(16-1S)/CR2,  and 
wild-type K562 cells, respectively, were 
lysed in NP-40 containing buffer. The 
])'sates were immunoadsorbed  with im- 
mobilized HB-5 (lanes 4-7) or irrele- 
vant IgG2a (lanes 8-11), and the im- 
mobilized complexes  were incubated 
with factor I and ml-C3b dimers for 
1 h at 37~  Cleavage of the 128I-C3b 
dimer was assessed by SDS-PAGE fol- 
lowed by autot~ography. The mI-C3b 
dimer was also incubated with (CR1)2- 
F(ab')z  alone  (lane  1),  with  factor  I 
alone (lane 2), and with (CR1)z-F(ab')2 
and factor I (lane 3). 8O 
20 
50  100  150  200  250 
Inhibitor  (nM) 
Competitive  inhibition  of specific nSI-pC3b binding  to  Figure  5. 
human E by incremental concentrations of (CR1)2-F(ab')2 (closed circles) 
and sCR1  (open circles). 
hibiting C3 convertase function.  In contrast  to these effects 
of (CR1)2-F(ab')2  on  the C3  and  C5  convertases  of the  al- 
ternative pathway, the chimera had no inhibitory activity in 
an  assay of classical  pathway  activation,  the  lysis  of IgM- 
sensitized sheep E in human serum (Fig.  8), consistent with 
its  lacking  the  C4b-binding  site of CR1. 
Discussion 
SCRs are present in 12 complement proteins that interact 
with at least one or more of the homologous proteins,  C3, 
C4, and C5 (28, 29), suggesting a unique role for this struc- 
tural motif in these interactions.  The presence of SCR.s only 
and no other structural  elements in some of these proteins, 
such as factor H  and the extracytoplasmic regions  of CR1, 
CR2,  and DAF,  was proof of this role, but it has not been 
possible to define a "standard" C3/C4/C5-binding  site having 
a  set number of SCR.s because of the wide variation of the 
occurrence  of these  structural  units  in  each protein  which 
ranges  from as many as 30 for the most  common  allotype 
of CR1  to  as  few  as  two  for Clr  and  Cls. 
Figure  6.  Factor I-cofactor  activity  of (CK1)2- 
F(ab')2 and sCK1. 12sI-C3b  dimers were incubated for 
1 h at 37~  with recombinant CR1 alone (lane I, 
A and B), with factor I (lane 2, A and B), or with 
factor I and incremental concentrations of (CK1)2- 
F(ab')2 and sCK1 (/1 and B, respectively;  lane 3, 2.50 
x  10 -TM;  lane 4,  6.25 x  10 -s M;  lane 5,  1.56 
x  10 -8 M; lane 6, 3.90  x  10 -9 M; lane 7, 9.76  ￿ 
10-10 M; lane 8, 2.44  x  10-10 M; lane 9, 6.10  x 
10 -11 M; lane 10, 1.52 x  10-11 M; and lane 11, 3.81 
x  10-12 M). 
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Figure 7.  Inhibition of zymosan-induced activation of the alternative 
pathway in human serum by incremental concentrations of (CR1)2-F(ab')2 
(closed circles) and sCR1 (open circles), respectively. Activation was assayed 
by  radioimmunoassay  of  the  concentrations  of  C3adesArg  (A)  and 
CSadesArg (B). 
CR2 was the first complement  protein in which the number 
of SCKs required for a ligand binding site was determined 
(30,  31). Chimeric proteins containing the NH2-terminal 
two SCRs of CR2 attached to either CR1 or a murine mAb 
were capable of binding the CR2 ligands, iC3b (18), C3dg, 
and the EBV (30), with affinities that were indistinguishable 
from those of the full-length 15-SCR or 16-SCR isoforms 
of the receptor. Constructs containing only the first or second 
SCR were inactive. When these observations  were consid- 
ered with earlier work demonstrating that both SCRs in a 
noncomplement protein, the II-2 receptor ot chain, were re- 
quired for binding I1-2 (32), and with the findings that no 
SCR-containing protein had fewer than two SCRs, it seemed 
possible  that a general  principle might be that the ligand 
binding sites of this family of proteins would be formed by 
two SCRs. Analogous studies of the C3b- and C4b-binding 
sites of CR1 had not been performed, but the demonstra- 
tion that the specificities of LHR-A and of LHRs-B and -C 
for C4b and C3b, respectively, were dependent on their respec- 
tive NH2-terminal two SCRs  (11), and that  substituting 
amino acids of SCR-1 and SCR-2 of LHR.-A with residues 
100 ￿84 
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Figure 8.  Inhibition of classical complement pathway-mediated lysis of 
IgM-sensitized sheep E in human serum by incremental concentrations 
of (CR1)z-F(ab')2 (closed circles) and sCR1 (open circles). 
from corresponding positions in SCR-8 and -9 of LHR-B 
led either to altered C4b-binding or to the acquisition of C3b 
binding (13), were interpreted as indicating that each binding 
site in CR1, like the single site in CR2, also would be formed 
by two SCRs. 
The original study (11) of the ligand-binding activities of 
the deletion mutants of CR1 had concluded that the specificity 
of the LHRs for C3b or C4b was determined by the first 
and second SCRs, and did not exclude possible contributions 
of other SCRs. In fact, its analysis of the structure of CR1 
was consistent with the possibility that the third and fourth 
SCRs of LHRs-A, -B, and -C had a role in ligand binding. 
They were the most highly conserved among all SCRs in 
the LHRs having this function, and they were not conserved 
in LHR-D, which had no demonstrable ligand binding ac- 
tivity. 
The present study now provides the functional correlate 
of this original structural analysis by demonstrating that only 
the CI~I/CR2 chimera containing the NH2-terminal four 
SCRs of LHR-B or -C had an affinity for C3b and factor 
I-cofactor activity that was comparable to full-length CR1. 
The chimera having only the first two SCRs had no detect- 
able C3b-binding activity (Table 1), addition of the third SCR 
formed a binding site having an affinity that was approxi- 
mately one-fourth that of the four SCR chimeras (Table 2; 
Fig.  2), and deletion of the first SCR from the four SCR 
chimeras severely impaired ligand-binding function (Tables 
1 and 2; Fig. 2). In addition, the factor I-cofactor function 
did not dearly segregate to one of the two chimeras having 
only three SCKs (Fig. 3). Thus, the C3b-binding site and, 
by inference, the C4b-binding site of CR1 differ from the 
iC3b/C3dg/EBV-binding site of CR2 by being constituted 
of four rather than of two SCRs, although binding activity 
could be demonstrated with three SCR forms. It is of in- 
terest that the two other membrane-associated RCA proteins 
with inhibitory activities, DAF and membrane cofactor pro- 
tein (MCP), contain four SCRs (29). The anatomy of an LHR 
can now be dissected into two SCRs that differentiate  be- 
1458  The C3b-binding Site of CP.1 tween C3b and C4b (11,  13),  followed by two SCRs that 
support binding of both C3b and C4b, and three SCRs that 
probably provide adequate spacing between the ligand-binding 
SCRs to allow multivalent interaction of CR1 with comple- 
ment-activating complexes containing multiple C3b and C4b 
molecules. 
A potential practical application of the mapping of the func- 
tional domains of CR1 to specific SCKs is the capacity to 
generate by molecular engineering  chimeric proteins com- 
bining  the complement  inhibitory  function  of CR1 with 
unique capabilities of the fusion partner.  The Ig molecule 
is especially suitable for carrying the active sites of CP,1. It 
effectively dimerizes these sites, thereby increasing the avidity 
of the recombinant protein for oligomeric or surface-bound 
C3b. The Ig molecule can target complement inhibition  to 
specific  tissues  through  its  antigenic  specificity,  and,  if a 
nonspecific antibody is used, it can extend temporally com- 
plement inhibition because of its long plasma half-life.  We 
have demonstrated the feasibility of this approach by finding 
that  the  (CR1)2-F(ab')2  chimera  (Fig.  4)  containing  two 
copies of the SCRs 8-11, the C3b-binding unit of CR1, was 
capable of binding both to antigen and pC3b (Fig. 5), serving 
as a cofactor for cleavage of C3b by factor I  (Fig.  6),  and 
inhibiting activation of the alternative pathway (Fig.  7). The 
absence of classical pathway inhibition by the chimera (Fig. 
8) emphasizes the important role that the C4b-binding site 
in sCR1 has for this function, and indicates that a chimeric 
CR1/Ig construct having the full inhibitory range of sCR1 
(9) must carry this site in addition to the C3b-binding domain. 
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